The EU AI Act now classifies virtually all AI systems used in hiring, performance management, and workforce planning as 'high-risk,' setting a new global standard for scrutiny. This means companies deploying AI workforce management systems face significant compliance burdens.
Billions flow into AI innovation for workforce and health. Yet, 'high-risk' classifications and mandatory audits simultaneously make deployment complex and costly. This tension creates a critical juncture for the industry.
Companies are trading speed for control and compliance. Those failing to adapt quickly will find their innovative edge blunted by regulatory hurdles.
Global Reach, Local Impact: Who's Under Scrutiny?
- The EU AI Act has extraterritorial effects, potentially covering employers outside Europe if their systems process or influence decisions involving EU-based workers or candidates, according to HR Executive.
- New York City's Local Law 144 requires employers using automated employment decision tools to complete annual independent bias audits and publicly disclose results, according to HR Executive.
These global and local laws mean nearly any company using AI in HR must now consider compliance. New York City's Local Law 144, mandating annual independent bias audits and public disclosure, sets a precedent. This will likely force AI developers to embed ethical design and transparency from the earliest stages, transforming AI development into a socio-legal challenge.
The Billion-Dollar Bet on AI
Assort Health, an AI agents platform, closed a $120 million Series C, bringing its total raised to $222 million and valuing the company at $1.2 billion, according to MarketScale. Cadence, a clinical AI company focused on chronic disease, secured $100 million in a Series C. Stepful, a company that trains healthcare workers, brought in $55 million in a Series C, according to MarketScale.
These funding rounds show strong market confidence in AI's transformative potential for healthcare and workforce solutions. However, the influx of billions into AI platforms, coupled with the December 2027 deadline for high-risk AI obligations, suggests a looming market correction. Many AI innovators will pivot from rapid growth to costly regulatory adherence, potentially stifling the very innovation investors currently fund.
Immediate Compliance Demands
Prohibitions 1-8 of the AI Act became effective in February 2025, with Prohibition 9 effective in December 2026, according to Shaping Europe’s digital future. Transparency rules for AI, requiring disclosure for chatbots and labeling for deep fakes, will come into effect in August 2026, according to Shaping Europe’s digital future.
Companies navigate initial prohibitions and must prepare for imminent transparency mandates. This mandates a rapid shift in operational requirements. Given the EU AI Act's 'high-risk' classification for HR and workforce AI, companies face a critical choice: reallocate significant R&D budgets towards compliance infrastructure and ongoing audits, or risk their innovative AI tools being deemed illegal for core business functions.
The Looming Deadline for High-Risk Systems
High-risk AI systems, including those for employment and worker management, will be subject to obligations such as risk assessment, data quality, and traceability starting December 2, 2027, according to Shaping Europe’s digital future.
The most stringent compliance requirements for AI systems in critical areas like employment are still ahead. Businesses must prepare proactively and comprehensively. By December 2027, Assort Health, valued at $1.2 billion, will need to demonstrate adherence to high-risk AI obligations to sustain its market position.
